Arbutus Biopharma (ABUS) Tax Provisions (2015 - 2022)

Arbutus Biopharma has disclosed Tax Provisions across 6 years of filings, most recently posting $4.4 million for Q1 2022.

• Tax Provisions for Q1 2022 came in at $4.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $4.4 million (changed N/A YoY), and the FY2022 annual result was $4.4 million, changed N/A from the prior year.
• Tax Provisions came in at $4.4 million for Q1 2022 at Arbutus Biopharma, up from -$12.7 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $4.4 million in Q1 2022 to a low of -$12.7 million in Q3 2019.
• The 3-year median for Tax Provisions is -$4.3 million (2018), against an average of -$4.2 million.
• Peak annual rise in Tax Provisions reached 195.56% in 2019, while the deepest fall reached 195.56% in 2019.
• Arbutus Biopharma's Tax Provisions stood at -$4.3 million in 2018, then sank by 195.56% to -$12.7 million in 2019, then jumped by 135.11% to $4.4 million in 2022.
• The last three Tax Provisions figures came in at $4.4 million (Q1 2022), -$12.7 million (Q3 2019), and -$4.3 million (Q3 2018), per Business Quant data.